Reviewing Aptevo Therapeutics Inc. (APVO)’s and CytomX Therapeutics Inc. (NASDAQ:CTMX)’s results

We will be comparing the differences between Aptevo Therapeutics Inc. (NASDAQ:APVO) and CytomX Therapeutics Inc. (NASDAQ:CTMX) as far as dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aptevo Therapeutics Inc. 19.54M 1.78 49.36M -2.21 0.00
CytomX Therapeutics Inc. 59.50M 8.08 84.60M -1.93 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows Aptevo Therapeutics Inc. and CytomX Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aptevo Therapeutics Inc. -252.61% -78.8% -51.1%
CytomX Therapeutics Inc. -142.18% -48.5% -9.4%

Liquidity

The current Quick Ratio of Aptevo Therapeutics Inc. is 3.7 while its Current Ratio is 3.9. Meanwhile, CytomX Therapeutics Inc. has a Current Ratio of 5.5 while its Quick Ratio is 5.5. CytomX Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Aptevo Therapeutics Inc.

Analyst Ratings

The Ratings and Recommendations for Aptevo Therapeutics Inc. and CytomX Therapeutics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aptevo Therapeutics Inc. 0 0 0 0.00
CytomX Therapeutics Inc. 0 0 1 3.00

Competitively CytomX Therapeutics Inc. has a consensus target price of $25, with potential upside of 134.52%.

Insider & Institutional Ownership

The shares of both Aptevo Therapeutics Inc. and CytomX Therapeutics Inc. are owned by institutional investors at 32.2% and 86.7% respectively. 1% are Aptevo Therapeutics Inc.’s share held by insiders. On the other hand, insiders held about 0.2% of CytomX Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aptevo Therapeutics Inc. -12.8% -10.63% -37% -72.97% -52.96% 12.6%
CytomX Therapeutics Inc. -44.83% -37.75% -25.56% -54.65% -64.48% -30%

For the past year Aptevo Therapeutics Inc. had bullish trend while CytomX Therapeutics Inc. had bearish trend.

Summary

CytomX Therapeutics Inc. beats Aptevo Therapeutics Inc. on 9 of the 11 factors.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. Its other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188. In addition, the company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., M D Anderson Cancer Center, Pfizer Inc., and The University of Texas to develop Probody therapeutics. It also has a strategic collaboration with Amgen Inc. to co-develop a CytomX Probody T-cell engaging bispecific against the epidermal growth factor receptor, a validated oncology target expressed on multiple human cancer types. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.